Status:
NOT_YET_RECRUITING
Recurrence in Patients With Differentiated Thyroid Cancer
Lead Sponsor:
Assiut University
Conditions:
Differentiated Thyroid Cancer
Eligibility:
All Genders
Brief Summary
The aim of this study is to assess the recurrence-free survival (RFS) rate and recurrence-related factors, especially the relationship between RFS and RAI dose, in patients who received RAI after thyr...
Detailed Description
Thyroid cancer is the most frequent cancer of the endocrine system, and its incidence is constantly rising worldwide. This is mainly because of advances in examination modalities that have made it pos...
Eligibility Criteria
Inclusion
- Patients with DTC (differentiated thyroid cancer) who underwent total or subtotal thyroidectomy without distant metastasis and gross residual tumors.
- Followed by ablation with RAI and underwent post RAI whole body scan.
- Having baseline TG (thyroglobulin), Anti-TG antibodies (anti thyroglobulin) and neck US.
- Patients with lymph node metastasis will be included if their lymph nodes had been dissected and no unresectable disease remained.
Exclusion
- Patients who received RAI and missed follow-up.
- Patients with no surgical or pathological data.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06154863
Start Date
March 1 2024
End Date
March 1 2026
Last Update
February 20 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.